Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.
about
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvOptimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based DesignCross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env GeneRedesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.Antibody 10-1074 suppresses viremia in HIV-1-infected individualsPentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesImpact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones.Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopesAntibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialLack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodiesComparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein BoostComprehensive Characterization of the Transmitted/Founder env Genes From a Single MSM Cohort in China.Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.Structural Determinants for the Selective Anti-HIV-1 Activity of the All-β Alternative Conformer of XCL1.Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env SequencesOptimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive ImmunizationDose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodiesMapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.Short Communication: Exploring Antibody Potential as Prophylactic/Therapeutic Strategies for Prevention of Early Mucosal HIV-1 Infection.Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site.HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell ResponsesCombined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk.Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year GapImportance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy.Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral TherapyEnhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors.Structural basis for membrane anchoring of HIV-1 envelope spikeTissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques.DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies.Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques.A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.
P2860
Q27644383-A5E6FD4A-9133-4849-92FF-83C6D9AF411EQ27644646-B0DA628B-8FD3-41D2-AFFF-238EBFF36EACQ28554907-673CD701-1BF7-4B58-AA67-7FC2065E8275Q30657338-F91220FD-B317-4ACB-9820-0E8B7EECEDECQ33786443-1CA057CA-6B43-46DF-862A-D5731DF30557Q33804531-96311238-8B26-409E-A6D9-012B3E5939ECQ34392963-40B4474C-2852-404F-8B69-1873E312BBB0Q34593647-F5678240-2768-475C-A2C0-86EAA6112E57Q34762224-D00EEA74-7EED-410E-A96A-51A1DEDE6BE2Q34791232-44C63DD5-0130-4064-9B6F-88F9D35618B3Q35073270-2EFE4AD6-4F99-4466-8666-AB688E2DF812Q35076711-F99308CB-E3B8-4355-8E71-F1277FD4EACAQ35076748-A0FABCB1-1659-422C-B5E0-AFC88C6287C7Q35140001-9E347E38-25F4-4977-A367-DD5C6CBC78F1Q35167400-F857E5B2-99AF-4B6A-A8BA-58F415FE8B56Q35760486-1442C38F-5EE9-4DF3-B31F-30CD24734AD1Q35788320-AA17BBBD-B5F0-43B1-B471-F0E9F65AA0B8Q35861276-D24BD2A8-DF05-4158-A802-B64121F26A26Q35913867-CBBD8FE7-6B63-44C1-9825-69E3147406C5Q35915764-A9394501-F539-49D1-B897-83412063AC96Q35974269-EC6E850C-3ED3-4B02-AA2B-B7469D141A1EQ36012177-1827FC1E-E5CC-4C5B-8B4D-86C9A97B21D4Q36081789-3F9B7F3D-04A2-430C-8F80-C74E93DABAABQ36105672-CE7E1589-C4D2-4381-A50B-7DC8F346EBC0Q36239578-BB8D2CFD-3817-403D-81DD-5B5D59F78C52Q36294701-44D1F415-AD39-4F44-AF42-2584FC3D7398Q36294727-709D0E14-FF51-4D22-B91C-8CB79DE31C01Q36446733-CA23226C-2843-4D0D-83F5-3673C93FDE9AQ36736860-CE302ED1-7461-4113-B08B-0FA79754C740Q36878930-EE5E3402-F3CC-4910-A045-C8A731A64839Q36973948-AC52B361-E9E1-4742-ACD1-02C684589BD2Q36978467-C937DAD4-B23F-45F0-8721-831983F11EE4Q37069793-21B8B924-106E-4C8A-BEB5-E784EC0B0AB0Q37091564-EA240407-A8AA-4DD2-85BF-7A02DF3291E9Q37286064-7DD79AAC-453D-4725-BFDC-495843AB0077Q37376640-F5311458-D70E-4B81-997E-D720F8F64506Q37469197-A2EB0F22-D4C4-439F-8AB3-7A2417A3676CQ37619109-595D70C6-A1D2-4628-8136-5A3071019C04Q37643792-83932408-67B6-4CBE-8DF7-A028724D5C51Q37656908-50A3475A-1961-455E-ADDC-73BEB2B99790
P2860
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Optimization and validation of ...... zing antibodies against HIV-1.
@ast
Optimization and validation of ...... zing antibodies against HIV-1.
@en
type
label
Optimization and validation of ...... zing antibodies against HIV-1.
@ast
Optimization and validation of ...... zing antibodies against HIV-1.
@en
prefLabel
Optimization and validation of ...... zing antibodies against HIV-1.
@ast
Optimization and validation of ...... zing antibodies against HIV-1.
@en
P2093
P2860
P50
P1476
Optimization and validation of ...... zing antibodies against HIV-1.
@en
P2093
Chen-li Lin
Christopher A Todd
Daniel A Ozaki
Ellen Turk
Hongmei Gao
Kelli M Greene
Marcella Sarzotti-Kelsoe
Michael S Seaman
Miroslawa Bilska
Robert T Bailer
P2860
P304
P356
10.1016/J.JIM.2013.11.022
P577
2013-12-01T00:00:00Z